The plummeting cost of genome sequencing may likely spur a jump in healthcare spending, Forbes contributor Peter Ubel says, and he thinks that maybe something ought to be done about that.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Pair of Them

To Tell?

Human Knockouts

Following the Curve

This Week in Nature

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.